Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the developing challenges facing patentability in the life sciences field.
If biotech companies in Brazil understand that they can use both plant variety and patent protection in certain cases, their ability to innovate may improve, says Gabriel Di Blasi of Di Blasi, Parente & Associados.
Precision medicine has come a long way since the completion of the Human Genome Project in 2003, but how have IP regimes developed in this area, asks Sheena Linehan of Potter Clarkson.
An advice system for labelling products in Mexico has been extended to food and non-alcoholic beverages. Daniel Sanchez and Victor Ramirez of Olivares report on how the regime works in practice.
The formal requirements for priority have become a hot topic at the European Patent Office, driven by their importance in high-profile oppositions to the Broad Institute’s CRISPR/Cas9 patents, as Catherine Coombes of HGF explains.
A disagreement over how pharma patents in Brazil are examined seems to have come to an end, as Breno Souza, Luisa Rezende and Silvia Costa of Clarke Modet & Co Brazil report.
European developments surrounding the patentability of plants and animals have become rather political, but there are ways for patentees to mitigate the effects of political influence over the patenting process, writes Jane Wainwright of Potter Clarkson.
A new law on supplementary protection certificates will be implemented on April 1, with the application, prosecution and maintenance of SPCs taking centre stage. José Manuel González of Clarke, Modet & Co reports.
President Trump’s decision to pull the US out of the Trans-Pacific Partnership trade deal may have particularly pernicious consequences for the pharmaceutical and biotechnology industries, writes Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff.
Anyone drafting patent licence agreements should follow several tips in order to avoid or better prepare for litigation later on, says Jessamyn Berniker of Williams & Connolly.